Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating IMB-1018972 for safety, tolerability, and efficacy in non-obstructive hypertrophic cardiomyopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-obstructive Hypertrophic Cardiomyopathy

Drugs mentioned

• IMB-1018972

Snippet

Sponsor: Imbria Pharmaceuticals, Inc. | Conditions: Non-obstructive Hypertrophic Cardiomyopathy | Phase 2 | Status: COMPLETED